Compare Ryanair Holdings plc (RYAAY) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ryanair Holdings plc vs 10X Genomics Inc — how do they compare? Ryanair Holdings plc trades at $58.99 (market cap $29.31B), while 10X Genomics Inc trades at $47.2 (market cap $5.48B). The key difference: Ryanair Holdings plc is far larger — about 5.3× 10X Genomics Inc's market cap, and Ryanair Holdings plc pays a 1.68% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| RYAAY | TXG | |
|---|---|---|
Market Cap | $29.31B | $5.48B |
Sector | Industrials | Health |
52-Week High | $73.82 | $45.80 |
52-Week Low | $53.24 | $11.34 |
Enterprise Value | $26.33B | $5.02B |
Dividend Yield | 1.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RYAAY trades at $58.80, down 6.03% amid a bearish technical signal. Recent Q1 2027 earnings missed expectations due to lower fares and higher fuel costs, though the company maintains strong profitability with a 13.98% net margin. Analyst consensus remains positive with 62.5% buy ratings, citing long-term advantages despite near-term headwinds from geopolitical tensions and industry volatility.
The outlook is cautious short-term given earnings pressure and technical weakness, but the strong balance sheet and potential industry consolidation offer recovery potential. Key risks include fuel price volatility and competitive fare pressures, while institutional sentiment suggests the sell-off may be overdone for value-oriented investors.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
